Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-01-11
|
rosmantuzumab - OMP-131R10 (anti-RSPO3 antibody) |
advanced refractory solid tumors, metastatic colorectal cance |
1 |
OncoMed Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2016-01-08
|
rosmantuzumab - OMP-131R10 (anti-RSPO3 antibody) |
|
|
OncoMed Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2016-01-07
|
BIND-014 (docetaxel encapsulated in a polymeric nanoparticle) |
metastatic castrate-resistant prostate cancer |
2 |
Bind Therapeutics (USA - MA) |
Cancer - Oncology |
2016-01-07
|
daratumumab |
multiple myeloma patients who have received at least three different lines of therapy including both a proteasome inhibitor and an immunomodulatory agent (IMiD) or who are double refractory to a proteasome inhibitor and an IMiD |
2 |
Janssen Biotech, a J&J company (USA - NJ) Genmab (Denmark) |
Cancer - Oncology - Rare diseases |
2016-01-07
|
99mTc-MIP-1404 |
prostate cancer |
3 |
Progenics Pharmaceuticals (USA - NY) |
Cancer - Oncology - Diagnostic |
2016-01-07
|
Traumakine® - FP-1201 (human recombinant interferon-beta 1a) |
acute respiratory distress syndrome (ARDS) |
2 |
Faron Pharmaceuticals (Finland) Maruishi Pharmaceutical (Japan) |
Lung diseases - Respiratory diseases - Rare diseases |
2016-01-07
|
ARC-520 |
hepatitis B |
2b |
Arrowhead Research Corporation (USA - CA) |
Infectious diseases |
2016-01-06
|
SENS-218 |
acute or chronic inner ear lesions either from vestibular or cochlear lesions |
1 |
Sensorion (France) |
Otorhinolaryngology |
2016-01-06
|
Baxdela® (delafloxacin) |
community-acquired bacterial pneumonia (CABP) |
3 |
Melinta Therapeutics (USA - CT) |
Infectious diseases |
2016-01-06
|
Ruconest® (C1 Esterase Inhibitor or rhC1INH - conestat alfa) |
attack prophylaxis in patients with hereditary angioedema (HAE) |
2 |
Pharming (The Netherlands) - Salix Pharmaceuticals (USA - NC) |
Rare diseases - Genetic diseases - Hematological diseases |
2016-01-06
|
pamrevlumab (FG-3019) |
Duchenne muscular dystrophy |
2 |
FibroGen (USA - CA) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2016-01-06
|
NBS20 -CLBS20 - (eltrapuldencel-T) |
stage III recurrent or stage IV metastatic melanoma |
3 |
NeoStem (USA - NY) |
Cancer - Oncology |
2016-01-05
|
Baremsis™ - APD421 (amisulpride - intravenous formulation of a currently marketed dopamine D2 antagonist for the new use of prevention and treatment of nausea & vomiting) |
prevention of post-operative nausea & vomiting (PONV) in high-risk patients |
3 |
Acacia Pharma (UK) |
Gastrointestinal diseases - Digestive diseases |
2016-01-05
|
NBTXR3 |
|
preclinical |
Nanobiotix (France) |
Cancer - Oncology |
2016-01-05
|
simtuzumab |
idiopathic pulmonary fibrosis (IPF) |
2 |
Gilead Sciences (USA - CA) |
Lung diseases - Respiratory diseases - Rare diseases |
2016-01-05
|
simtuzumab |
idiopathic pulmonary fibrosis (IPF) |
2 |
Gilead Sciences (USA - CA) |
Lung diseases - Respiratory diseases - Rare diseases |
2016-01-04
|
NBTXR3 |
prostate cancer |
1-2 |
Nanobiotix (France) |
Cancer - Oncology |
2015-12-30
|
tazemetostat - EPZ-6438 (E7438) |
genetically defined tumors including INI1-negative tumors, certain SMARCA4-negative tumors and synovial sarcomas |
2 |
Epizyme (USA - MA) Eisai (Japan) |
Cancer - Oncology |
2015-12-23
|
TG4010 (MVA-MUC1-IL2) |
advanced non-small cell lung cancer |
2b-3 |
Transgene (France) |
Cancer - Oncology |
2015-12-23
|
Adcetris® (brentuximab vedotin) and Opdivo® (nivolumab) |
relapsed or refractory CD30-expressing non-Hogkin lymphoma |
1-2a |
Seattle Genetics (USA - WA) BMS (USA - NY) |
Cancer - Oncology |